These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 35787987)

  • 1. Clinical impact of time-to-positivity of blood cultures on mortality in patients with Pseudomonas aeruginosa bacteremia.
    Rolo M; Martín-Higuera MC; Viedma E; Villa J; Mancheño-Losa M; Lora-Tamayo J; Chaves F; Orellana MÁ; Recio R
    J Glob Antimicrob Resist; 2022 Sep; 30():269-275. PubMed ID: 35787987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of time to positivity of blood culture in children with Pseudomonas aeruginosa bacteremia.
    Xu H; Cheng J; Yu Q; Li Q; Yi Q; Luo S; Li Y; Zhang G; Tian X; Cheng D; Luo Z
    BMC Infect Dis; 2020 Sep; 20(1):665. PubMed ID: 32907533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-to-positivity of blood culture: An independent prognostic factor of monomicrobial Pseudomonas aeruginosa bacteremia.
    Tang PC; Lee CC; Li CW; Li MC; Ko WC; Lee NY
    J Microbiol Immunol Infect; 2017 Aug; 50(4):486-493. PubMed ID: 26455486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
    Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic roles of time to positivity of blood cultures in patients with
    Chen Y; Huang X; Wu A; Lin X; Zhou P; Liu Y; Wu Y; Fu C; Dou Q; Jiang H
    Epidemiol Infect; 2020 May; 148():e101. PubMed ID: 32381131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
    Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes.
    Tam VH; Rogers CA; Chang KT; Weston JS; Caeiro JP; Garey KW
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3717-22. PubMed ID: 20585122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time to positivity of blood culture is a risk factor for clinical outcomes in Staphylococcus aureus bacteremia children: a retrospective study.
    Li Y; Li Q; Zhang G; Ma H; Wu Y; Yi Q; Jiang L; Wan J; Suo F; Luo Z
    BMC Infect Dis; 2019 May; 19(1):437. PubMed ID: 31101087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time to positivity as prognostic tool in patients with Pseudomonas aeruginosa bloodstream infection.
    Willmann M; Kuebart I; Vogel W; Flesch I; Markert U; Marschal M; Schröppel K; Autenrieth IB; Hölzl F; Peter S
    J Infect; 2013 Nov; 67(5):416-23. PubMed ID: 23817209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current time-to-positivity of blood cultures in febrile neutropenia: a tool to be used in stewardship de-escalation strategies.
    Puerta-Alcalde P; Cardozo C; Suárez-Lledó M; Rodríguez-Núñez O; Morata L; Fehér C; Marco F; Del Río A; Martínez JA; Mensa J; Rovira M; Esteve J; Soriano A; Garcia-Vidal C
    Clin Microbiol Infect; 2019 Apr; 25(4):447-453. PubMed ID: 30096417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extensively drug-resistant Pseudomonas aeruginosa bacteremia in solid organ transplant recipients.
    Bodro M; Sabé N; Tubau F; Lladó L; Baliellas C; González-Costello J; Cruzado JM; Carratalà J
    Transplantation; 2015 Mar; 99(3):616-22. PubMed ID: 25119130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to positivity in blood cultures of adults with nontyphoidal Salmonella bacteremia.
    Lin HW; Hsu HS; Huang YT; Yang CJ; Hsu MS; Liao CH
    J Microbiol Immunol Infect; 2016 Jun; 49(3):417-23. PubMed ID: 25311404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and bacterial characteristics of Pseudomonas aeruginosa affecting the outcome of patients with bacteraemic pneumonia.
    Recio R; Viedma E; González-Bodí S; Villa J; Orellana MÁ; Mancheño-Losa M; Lora-Tamayo J; Chaves F
    Int J Antimicrob Agents; 2021 Dec; 58(6):106450. PubMed ID: 34644604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
    Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
    J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High pyocyanin production and non-motility of Pseudomonas aeruginosa isolates are correlated with septic shock or death in bacteremic patients.
    Gupte A; Jyot J; Ravi M; Ramphal R
    PLoS One; 2021; 16(6):e0253259. PubMed ID: 34115807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk Factors for Mortality among Patients with
    Montero MM; López Montesinos I; Knobel H; Molas E; Sorlí L; Siverio-Parés A; Prim N; Segura C; Duran-Jordà X; Grau S; Horcajada JP
    J Clin Med; 2020 Feb; 9(2):. PubMed ID: 32074947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of virulence genotype and resistance profile in the mortality of Pseudomonas aeruginosa bloodstream infections.
    Peña C; Cabot G; Gómez-Zorrilla S; Zamorano L; Ocampo-Sosa A; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez-López F; Tubau F; Martínez-Martínez L; Oliver A;
    Clin Infect Dis; 2015 Feb; 60(4):539-48. PubMed ID: 25378459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections.
    Peña C; Suarez C; Gozalo M; Murillas J; Almirante B; Pomar V; Aguilar M; Granados A; Calbo E; Rodríguez-Baño J; Rodríguez F; Tubau F; Martínez-Martínez L; Oliver A;
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1265-72. PubMed ID: 22155832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to positivity of blood cultures supports early re-evaluation of empiric broad-spectrum antimicrobial therapy.
    Lambregts MMC; Bernards AT; van der Beek MT; Visser LG; de Boer MG
    PLoS One; 2019; 14(1):e0208819. PubMed ID: 30601829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa.
    Corbella L; Boán J; San-Juan R; Fernández-Ruiz M; Carretero O; Lora D; Hernández-Jiménez P; Ruiz-Ruigómez M; Rodríguez-Goncer I; Silva JT; López-Medrano F; Lizasoain M; Villa J; Caro-Teller JM; Aguado JM
    Int J Antimicrob Agents; 2022 Feb; 59(2):106517. PubMed ID: 34990760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.